US label update for AstraZeneca/B-MS' Onglyza for renally-impaired diabetics The Pharma Letter The renal study investigated the safety and efficacy of Onglyza in patients with moderate to severe renal impairment or end-stage renal disease (ESRD). Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe. and more »

...